Skip to Main Content


Skip Nav Destination

Chronic Leukemias

December 20, 2021

A collection of features and news articles published in ASH Clinical News related to chronic leukemias.


Immune Response Muted in Patients With NHL/CLL Who Are Vaccinated Against COVID-19

Because patients with non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL), a subtype of NHL, have both a higher risk of poor outcomes from COVID-19 and immune system defects as a result of their therapy and cancer itself...

Nilotinib Demonstrates Greater Efficacy Than Imatinib in CML

Treatment with nilotinib was more effective in inducing deep molecular response (MR 4.5) than imatinib for patients with chronic myeloid leukemia...

Updated Results from the Phase I/II Study of Pirtobrutinib for Previously Treated CLL/SLL

Pirtobrutinib was shown to have efficacy in patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were previously treated with a Bruton tyrosine kinase inhibitor...

Fixed-Duration Venetoclax Consolidation Does Not Improve Responses After Venetoclax Plus Obinutuzumab in CLL

A 12-cycle venetoclax consolidation regimen following fixed-duration venetoclax plus obinutuzumab increased the duration of side effects and did not prevent the loss of measurable residual disease (MRD)-negative response and disease relapse risk in patients with previously untreated chronic lymphocytic leukemia...

Ibrutinib, Venetoclax, and Obinutuzumab Triplet Shows Promise for Untreated, High-Risk CLL

A triple combination of ibrutinib, venetoclax, and obinutuzumab led to high rates of complete response (CR) and estimated 24-month survival in patients with untreated high-risk chronic lymphocytic leukemia...

Ibrutinib Prolongs Time to Progression in Early-Stage CLL, More Data Needed to Determine Survival Benefit

Bruton tyrosine kinase inhibitor ibrutinib significantly improved event-free survival (EFS) in patients with early-stage chronic lymphocytic leukemia (CLL) and unfavorable prognostic factors...







Connect with us:

September 2022


Close Modal

or Create an Account

Close Modal
Close Modal